Chowdhury 2018 Oxid Med Cell Longev: Difference between revisions

From Bioblast
No edit summary
No edit summary
Line 8: Line 8:
|editor=Gnaiger E
|editor=Gnaiger E
}}
}}
== Correction: FADH<sub>2</sub> and S-pathway ==
[[File:Chowdhury 2018 Oxid Med Cell Longev CORRECTION.png|400px|right]]
::::* [[Complex II ambiguities]]
{{Template:Correction FADH2 and S-pathway}}
Β 
:::: [[File:Chowdhury 2018 Oxid Med Cell Longev CORRECTION.png|800px]]
Β 
:::: A commonly found error on FADH<sub>2</sub> in the S-pathway requires correction. For clarification, see page 48 in [[Gnaiger_2020_BEC_MitoPathways |Gnaiger (2020)]]
::::* Quote (p 48): "TheΒ  substrateΒ  ofΒ  CIIΒ  isΒ  succinate,Β  whichΒ  isΒ  oxidizedΒ  formingΒ  fumarateΒ  while reducing flavin adenine dinucleotide FAD to FADH<sub>2</sub>, with further electron transfer to the quinone pool. Whereas reduced NADH is a substrate of Complex I linked to dehydrogenases of the TCA cycle and mt-matrix upstream of CI,Β  reducedΒ  FADH<sub>2</sub> is a product of Complex II with downstream electron flow from CII to Q."
Β 
:::::: Gnaiger E (2020) Mitochondrial pathways and respiratory control. An introduction to OXPHOS analysis. 5th ed. Bioenerg Commun 2020.2. https://doi.org/10.26124/bec:2020-0002


{{Labeling
{{Labeling

Revision as of 13:42, 19 March 2023

Publications in the MiPMap
Roy Chowdhury S, Banerji V (2018) Targeting mitochondrial bioenergetics as a therapeutic strategy for chronic lymphocytic leukemia. Oxid Med Cell Longev 2018:2426712. doi: 10.1155/2018/2426712

Β» PMID: 29682155 Open Access

Roy Chowdhury S, Banerji V (2018) Oxid Med Cell Longev

Abstract: Altered cellular metabolism is considered a hallmark of cancer and is fast becoming an avenue for therapeutic intervention. Mitochondria have recently been viewed as an important cellular compartment that fuels the metabolic demands of cancer cells. Mitochondria are the major source of ATP and metabolites necessary to fulfill the bioenergetics and biosynthetic demands of cancer cells. Furthermore, mitochondria are central to cell death and the main source for generation of reactive oxygen species (ROS). Overall, the growing evidence now suggests that mitochondrial bioenergetics, biogenesis, ROS production, and adaptation to intrinsic oxidative stress are elevated in chronic lymphocytic leukemia (CLL). Hence, recent studies have shown that mitochondrial metabolism could be targeted for cancer therapy. This review focuses the recent advancements in targeting mitochondrial metabolism for the treatment of CLL.

β€’ Bioblast editor: Gnaiger E

Chowdhury 2018 Oxid Med Cell Longev CORRECTION.png

Correction: FADH2 and Complex II

Ambiguity alert.png
FADH2 is shown as the substrate feeding electrons into Complex II (CII). This is wrong and requires correction - for details see Gnaiger (2024).
Gnaiger E (2024) Complex II ambiguities ― FADH2 in the electron transfer system. J Biol Chem 300:105470. https://doi.org/10.1016/j.jbc.2023.105470 - Β»Bioblast linkΒ«


Labels: MiParea: Respiration, Pharmacology;toxicology  Pathology: Cancer 







Cookies help us deliver our services. By using our services, you agree to our use of cookies.